Regeneron, Bayer Lose Eye Med Biosimilar Battle
A London court on Monday refused Regeneron and Bayer's attempt to stop a biosimilar company infringing their extended patent protections for eye medicine aflibercept by producing a replica version in the...To view the full article, register now.
Already a subscriber? Click here to view full article